CL2013001101A1 - Compuestos derivados de rasagilina enriquecida con deuterio; su proceso de preparacion; mezcla de al menos dos compuestos enriquecidos con deuterio; composicion farmaceutica que los comprende, util para tratar un trastorno neurodegenerativo tal como mal de parkinson, sindrome de piernas inquietas, perdida auditiva y disfuncion olfativa. - Google Patents

Compuestos derivados de rasagilina enriquecida con deuterio; su proceso de preparacion; mezcla de al menos dos compuestos enriquecidos con deuterio; composicion farmaceutica que los comprende, util para tratar un trastorno neurodegenerativo tal como mal de parkinson, sindrome de piernas inquietas, perdida auditiva y disfuncion olfativa.

Info

Publication number
CL2013001101A1
CL2013001101A1 CL2013001101A CL2013001101A CL2013001101A1 CL 2013001101 A1 CL2013001101 A1 CL 2013001101A1 CL 2013001101 A CL2013001101 A CL 2013001101A CL 2013001101 A CL2013001101 A CL 2013001101A CL 2013001101 A1 CL2013001101 A1 CL 2013001101A1
Authority
CL
Chile
Prior art keywords
deuterium
enriched
compounds
rasagiline
parkinson
Prior art date
Application number
CL2013001101A
Other languages
English (en)
Spanish (es)
Inventor
Eliezer Bahar
Anton Frenkel
Victor Piryatinsky
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45973513&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013001101(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of CL2013001101A1 publication Critical patent/CL2013001101A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/57Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton
    • C07C211/60Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton containing a ring other than a six-membered aromatic ring forming part of at least one of the condensed ring systems
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02Amines; Quaternary ammonium compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001Acyclic or carbocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Psychology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CL2013001101A 2010-10-26 2013-04-22 Compuestos derivados de rasagilina enriquecida con deuterio; su proceso de preparacion; mezcla de al menos dos compuestos enriquecidos con deuterio; composicion farmaceutica que los comprende, util para tratar un trastorno neurodegenerativo tal como mal de parkinson, sindrome de piernas inquietas, perdida auditiva y disfuncion olfativa. CL2013001101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40674010P 2010-10-26 2010-10-26

Publications (1)

Publication Number Publication Date
CL2013001101A1 true CL2013001101A1 (es) 2013-09-06

Family

ID=45973513

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013001101A CL2013001101A1 (es) 2010-10-26 2013-04-22 Compuestos derivados de rasagilina enriquecida con deuterio; su proceso de preparacion; mezcla de al menos dos compuestos enriquecidos con deuterio; composicion farmaceutica que los comprende, util para tratar un trastorno neurodegenerativo tal como mal de parkinson, sindrome de piernas inquietas, perdida auditiva y disfuncion olfativa.

Country Status (17)

Country Link
US (2) US20120101168A1 (enExample)
EP (1) EP2632254A4 (enExample)
JP (1) JP2014503480A (enExample)
KR (1) KR20140023872A (enExample)
CN (1) CN103188933A (enExample)
AU (1) AU2011320611A1 (enExample)
BR (1) BR112013010308A2 (enExample)
CA (1) CA2816104A1 (enExample)
CL (1) CL2013001101A1 (enExample)
EA (1) EA201390613A1 (enExample)
IL (1) IL225852A0 (enExample)
MX (1) MX2013004598A (enExample)
NZ (1) NZ610526A (enExample)
PH (1) PH12013500821A1 (enExample)
SG (2) SG10201508771TA (enExample)
WO (1) WO2012058219A2 (enExample)
ZA (1) ZA201303505B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1991214B1 (en) * 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
US8946300B2 (en) 2006-04-03 2015-02-03 Teva Pharmaceutical Industries, Ltd. Use of rasagilline for the treatment of restless legs syndrome
ATE528989T1 (de) * 2006-12-14 2011-11-15 Teva Pharma Kristalline feste rasagilin-base
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
NZ586025A (en) * 2008-01-11 2012-08-31 Teva Pharma Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
HRP20140845T1 (hr) 2009-07-09 2014-11-07 Ratiopharm Gmbh Soli rasagilina i farmaceutski pripravci od njih
US20110130466A1 (en) * 2009-10-09 2011-06-02 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
EP2939669A1 (en) * 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan
RU2013108256A (ru) 2010-07-27 2014-09-10 Тева Фармасьютикал Индастриз Лтд. Дисперсии цитрата разагилина
RU2587330C2 (ru) 2010-07-27 2016-06-20 Тева Фармасьютикал Индастриз Лтд. Применение разагилина для лечения обонятельной дисфункции
EA201490761A1 (ru) 2011-10-10 2014-11-28 Тева Фармасьютикал Индастриз Лтд. R(+)-n-формилпропаргиламиноиндан
US9339469B2 (en) 2011-10-10 2016-05-17 Teva Pharmaceutical Industries, Ltd. R(+)-N-methyl-propargyl-aminoindan
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤
JP7471298B2 (ja) * 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル-ロイシンの重水素化類似体
CN111323524B (zh) * 2020-04-08 2022-04-15 重庆华森制药股份有限公司 一种炔丙胺及其杂质的检测方法
CN115947675B (zh) * 2022-12-21 2024-05-31 博济医药科技股份有限公司 一种雷沙吉兰中间体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
EP1778196A4 (en) * 2004-07-26 2008-12-17 Teva Pharma PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
ES2371883T3 (es) * 2004-11-24 2012-01-11 Teva Pharmaceutical Industries Ltd. Composiciones de rasagilina de disgregación oral.
EP1851188A1 (en) * 2005-02-22 2007-11-07 Teva Pharmaceutical Industries Limited Improved process for the synthesis of enantiomeric indanylamine derivatives
JP2009514946A (ja) * 2005-11-06 2009-04-09 ブレイン ウォッチ エルティディ 磁気共鳴画像/分光手段およびその方法
CN102203053B (zh) * 2008-06-02 2015-11-25 基因里克斯(英国)有限公司 用于制备胺的改进方法
JP2011522892A (ja) * 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
WO2010054286A2 (en) * 2008-11-10 2010-05-14 Auspex Pharmaceuticals, Inc. Substituted hydroxyphenylamine compounds
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
US20100286124A1 (en) * 2009-04-10 2010-11-11 Auspex Pharmaceuticals, Inc. Prop-2-yn-1-amine inhibitors of monoamine oxidase type b
US20120156139A1 (en) * 2009-08-31 2012-06-21 Rachel Katz-Brull Isotopically labeled neurochemical agents and uses therof for diagnosing conditions and disorders

Also Published As

Publication number Publication date
MX2013004598A (es) 2013-07-17
SG189454A1 (en) 2013-05-31
NZ610526A (en) 2015-10-30
ZA201303505B (en) 2015-08-26
IL225852A0 (en) 2013-06-27
BR112013010308A2 (pt) 2016-07-05
US20140364506A1 (en) 2014-12-11
EP2632254A2 (en) 2013-09-04
SG10201508771TA (en) 2015-11-27
US20120101168A1 (en) 2012-04-26
KR20140023872A (ko) 2014-02-27
EP2632254A4 (en) 2015-08-05
CA2816104A1 (en) 2012-05-03
AU2011320611A1 (en) 2013-06-13
PH12013500821A1 (en) 2019-07-03
CN103188933A (zh) 2013-07-03
WO2012058219A2 (en) 2012-05-03
EA201390613A1 (ru) 2013-11-29
JP2014503480A (ja) 2014-02-13
WO2012058219A3 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
CL2013001101A1 (es) Compuestos derivados de rasagilina enriquecida con deuterio; su proceso de preparacion; mezcla de al menos dos compuestos enriquecidos con deuterio; composicion farmaceutica que los comprende, util para tratar un trastorno neurodegenerativo tal como mal de parkinson, sindrome de piernas inquietas, perdida auditiva y disfuncion olfativa.
CL2014003388A1 (es) Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades.
ECSP18048718A (es) Imidazolilimidazoles condensados como compuestos antivirales
ECSP11011517A (es) Compuestos antivirales
CL2015000956A1 (es) Compuestos derivados de pirrolotriazinona como inhibidores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; uso para tratar enfermedades respiratorias, autoinmunes, trastornos neurologicos, cardiovasculares, metabolicos, entre otros.
EA201270720A1 (ru) Модуляторы рецептора андрогенов и их применение
EA201491161A1 (ru) Фторированные модуляторы рецепторов эстрогенов и их применение
CL2007002572A1 (es) Compuestos derivados de benzotiazol, moduladores de quinasa; composicion farmaceutica que los contiene; y su uso para el tratamiento de un trastorno mediado por la quinasa c-jun-n-terminal, tales como trastornos autoinmunes, inflamatorios, metabolico
UY35334A (es) Compuestos y composiciones como degradantes selectivos del receptor de estrógeno
UY33735A (es) Compuestos antivirales
CL2013000714A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras.
CO6680663A2 (es) Composiciones pesticidas producidas de piranosas, composiciones que las contienen y su proceso de obtención
CL2015001699A1 (es) Compuestos derivados de nucleosidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y su uso para preparar un medicamento util en el tratamiento de la hepatitis c.
CL2014000806A1 (es) Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple.
CL2007002834A1 (es) Compuestos derivados de pirazina-2-carboxamida; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar trastornos relacionados con inflamacion, tales como artritis, intestino inflamado, alergia,
UY32571A (es) Compuestos derivados de pirazol amida
BRPI1011043B8 (pt) fenilureias e fenilamidas substituídas como ligantes de receptor de vaniloide, seus usos e seu processo de preparação, e composição farmacêutica
CL2013001604A1 (es) Compuestos derivados de pirimidinona sustituida; composicion farmaceutica que los comprende; su uso para tratar la enfermedad de alzheimer y la aterosclerosis.
CL2015000946A1 (es) Compuestos derivados de quinolinilo unidos a fenilo; composicion farmaceutica y su proceso de elaboracion; un metodo para tratar o mejorar un sindrome trastorno, o enfermedad inflamatoria mediada por ror-gamma-t, tal como artritis reumatoide, psoriasis, enfermedad de crohn, entre otras.
CL2008000330A1 (es) Compuestos derivados de octahidro fenantreno sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar asma, dermatitis, enfermedad de alzheimer, artritis, entre otras enfermedades.
CL2008002726A1 (es) Compuestos derivados de isoquinolinilo e isoindolinilo, antagonistas de histamina-3; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar trastornos del sistema nervioso c
CL2014003130A1 (es) Compuestos derivados de n-piridinil amidas ciclicas,inhibidores de quinasas pim; composicion farmaceutica que los comprende; combinacion farmaceutica; metodo para tratar enfermedades tales como canceres o un trastorno autoinmune.
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
BR112013005706A2 (pt) métodos para preparar um extrato refinado e um extrato purificado de centella asiatica
ECSP15013883A (es) Benzamidas